水晶光電(002273.SZ):水晶是LUMUS的股東也是業務夥伴
格隆匯7月27日丨有投資者向水晶光電(002273.SZ)提問:請問公司AR眼鏡亮點在哪裏?
水晶光電回覆:在AR領域除了傳統的攝像頭(包括3D攝像頭)元器件和傳感元器件之外,我們更加專注投影核心光學元器件和投影模組,公司有OEM和ODM兩種業務模式。反射光波導主要專利都集中在以色列科技公司LUMUS,水晶是LUMUS的股東也是業務夥伴。衍射光波導,有幾條業務路線,我們相信主流海外科技巨頭有自己的方案路線,水晶以OEM的形式與海外科技巨頭們進行業務合作。目前水晶也和美國digilens保持戰略業務合作關係,我們支付技術開發費用,以ODM方式為其他客户提供產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.